DE69410790D1 - Bicyclische ansamycine und ihre verwendung als antitumormittel - Google Patents

Bicyclische ansamycine und ihre verwendung als antitumormittel

Info

Publication number
DE69410790D1
DE69410790D1 DE69410790T DE69410790T DE69410790D1 DE 69410790 D1 DE69410790 D1 DE 69410790D1 DE 69410790 T DE69410790 T DE 69410790T DE 69410790 T DE69410790 T DE 69410790T DE 69410790 D1 DE69410790 D1 DE 69410790D1
Authority
DE
Germany
Prior art keywords
agents
antituary
ansamycins
bicyclic
bicyclic ansamycins
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69410790T
Other languages
English (en)
Other versions
DE69410790T2 (de
Inventor
Rodney Schnur
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Inc
Original Assignee
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc filed Critical Pfizer Inc
Publication of DE69410790D1 publication Critical patent/DE69410790D1/de
Application granted granted Critical
Publication of DE69410790T2 publication Critical patent/DE69410790T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DE69410790T 1993-04-07 1994-03-14 Bicyclische ansamycine und ihre verwendung als antitumormittel Expired - Fee Related DE69410790T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/044,521 US5387584A (en) 1993-04-07 1993-04-07 Bicyclic ansamycins
PCT/US1994/002546 WO1994022867A1 (en) 1993-04-07 1994-03-14 Bicyclic ansamycins and their use as antitumor agents

Publications (2)

Publication Number Publication Date
DE69410790D1 true DE69410790D1 (de) 1998-07-09
DE69410790T2 DE69410790T2 (de) 1998-10-01

Family

ID=21932854

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69410790T Expired - Fee Related DE69410790T2 (de) 1993-04-07 1994-03-14 Bicyclische ansamycine und ihre verwendung als antitumormittel

Country Status (10)

Country Link
US (1) US5387584A (de)
EP (1) EP0693073B1 (de)
JP (1) JP2722280B2 (de)
AT (1) ATE166877T1 (de)
CA (1) CA2160137C (de)
DE (1) DE69410790T2 (de)
DK (1) DK0693073T3 (de)
ES (1) ES2116594T3 (de)
FI (1) FI106028B (de)
WO (1) WO1994022867A1 (de)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6852496B1 (en) * 1997-08-12 2005-02-08 Oregon Health And Science University Methods of screening for agents that promote nerve cell growth
US5968921A (en) * 1997-10-24 1999-10-19 Orgegon Health Sciences University Compositions and methods for promoting nerve regeneration
JP2002520369A (ja) 1998-07-17 2002-07-09 アメリカ合衆国 水溶性薬剤およびその製造方法
US6747055B1 (en) 1998-07-17 2004-06-08 The United States Of America As Represented By The Department Of Health And Human Services Water-soluble drugs and methods for their production
ATE307601T1 (de) * 1998-12-07 2005-11-15 Ecosmart Technologies Inc Brustkrebsbehandlung mittels natürlicher ätherischer öle
AU2001292548B2 (en) 2000-07-28 2005-06-16 Sloan-Kettering Institute For Cancer Research Methods for treating cell proliferative disorders and viral infections
JP4406205B2 (ja) * 2000-11-02 2010-01-27 スローン−ケッタリング・インスティテュート・フォー・キャンサー・リサーチ Ｈｓｐ９０に結合するための小分子組成物
US7211562B2 (en) 2000-11-02 2007-05-01 Sloan-Kettering Institute For Cancer Research Methods for enhancing the efficacy of cytotoxic agents through the use of HSP90 inhibitors
AU2002252179A1 (en) * 2001-03-01 2002-09-19 Conforma Therapeutics Corp. Methods for treating genetically-defined proliferative disorders with hsp90 inhibitors
WO2002094196A2 (en) * 2001-05-23 2002-11-28 Sloan Kettering Institute For Cancer Research Method of treatment for cancers associated with elevated
US20090197852A9 (en) * 2001-08-06 2009-08-06 Johnson Robert G Jr Method of treating breast cancer using 17-AAG or 17-AG or a prodrug of either in combination with a HER2 inhibitor
US6872715B2 (en) * 2001-08-06 2005-03-29 Kosan Biosciences, Inc. Benzoquinone ansamycins
EP1923061A1 (de) 2001-09-24 2008-05-21 Conforma Therapeutic Corporation Verfahren zur Herstellung eines 17-Allyl-amino-Geldanamycins (17-AAG) und anderer Ansamycine
KR20040054692A (ko) * 2001-09-24 2004-06-25 콘포마 세러퓨틱스 코포레이션 17-알릴 아미노 겔다나마이신 (17-ａａｇ) 및 기타안사마이신의 제조 방법
US7261875B2 (en) 2001-12-21 2007-08-28 Board Of Regents, The University Of Texas System Dendritic poly (amino acid) carriers and methods of use
US7465718B2 (en) * 2002-02-08 2008-12-16 Conforma Therapeutics Corporation Ansamycins having improved pharmacological and biological properties
EP1492522A4 (de) * 2002-04-10 2009-01-14 Conforma Therapeutics Corp Ansamycin-formulierungen und verfahren zu ihrer herstellung und verwendung
US20060148776A1 (en) * 2003-03-13 2006-07-06 Conforma Therapeutics Corporation Drug formulations having long and medium chain triglycerides
US20050020556A1 (en) * 2003-05-30 2005-01-27 Kosan Biosciences, Inc. Method for treating diseases using HSP90-inhibiting agents in combination with platinum coordination complexes
US20050020557A1 (en) * 2003-05-30 2005-01-27 Kosan Biosciences, Inc. Method for treating diseases using HSP90-inhibiting agents in combination with enzyme inhibitors
US20050020534A1 (en) * 2003-05-30 2005-01-27 Kosan Biosciences, Inc. Method for treating diseases using HSP90-inhibiting agents in combination with antimetabolites
US7691838B2 (en) * 2003-05-30 2010-04-06 Kosan Biosciences Incorporated Method for treating diseases using HSP90-inhibiting agents in combination with antimitotics
US20050054625A1 (en) * 2003-05-30 2005-03-10 Kosan Biosciences, Inc. Method for treating diseases using HSP90-inhibiting agents in combination with nuclear export inhibitors
US20050026893A1 (en) * 2003-05-30 2005-02-03 Kosan Biosciences, Inc. Method for treating diseases using HSP90-inhibiting agents in combination with immunosuppressants
US20050054589A1 (en) * 2003-05-30 2005-03-10 Kosan Biosciences, Inc. Method for treating diseases using HSP90-inhibiting agents in combination with antibiotics
WO2005009345A2 (en) * 2003-06-13 2005-02-03 Kosan Biosciences, Inc. 2-desmethyl ansamycin compounds
CN100404029C (zh) * 2003-09-25 2008-07-23 中国医学科学院医药生物技术研究所 格尔德霉素（c-3559）在制备疱疹病毒生殖道感染药物中的应用
US6855705B1 (en) 2003-11-12 2005-02-15 Kosan Biosciences, Inc. 11-O-methylgeldanamycin compounds
US6875863B1 (en) 2003-11-12 2005-04-05 Kosan Biosciences, Inc. 11-O-methylgeldanamycin compounds
US6887993B1 (en) 2003-11-12 2005-05-03 Kosan Biosciences, Inc. 11-O-methylgeldanamycin compounds
EP1682514A4 (de) 2003-11-12 2008-07-16 Kosan Biosciences Inc 11- o-methylgeldanamycinverbindungen
US20060019941A1 (en) * 2003-12-23 2006-01-26 Infinity Pharmaceuticals, Inc. Analogs of benzoquinone-containing ansamycins and methods of use thereof
US7282493B2 (en) 2003-12-23 2007-10-16 Infinity Pharmaceuticals, Inc. Analogs of benzoquinone-containing ansamycins and methods of use thereof
US7491701B2 (en) * 2004-01-27 2009-02-17 Boys Town National Research Hospital Peptides that bind to HSP90 proteins
WO2006034147A2 (en) * 2004-09-16 2006-03-30 Abraxis Bioscience, Inc. Compositions and methods for the preparation and administration of poorly water soluble drugs
US20060067953A1 (en) * 2004-09-29 2006-03-30 Conforma Therapeutics Corporation Oral pharmaceutical formulations and methods for producing and using same
NZ561939A (en) * 2005-03-30 2011-03-31 Conforma Therapeutics Corp Alkynyl pyrrolopyrimidines and related analogs as HSP90-inhibitors
BRPI0608661A2 (pt) * 2005-04-07 2010-01-19 Conforma Therapeutics Corp formulaÇço farmacÊutica, uso de formulaÇço farmacÊutica, e, mÉtodo de preparaÇço de uma formulaÇço farmacÊutica
MX2007013499A (es) * 2005-04-29 2008-01-24 Kosan Biosciences Inc Metodo para tratar mieloma multiple utilizando 17-aag o 17-ag o un profarmaco de ya sea 17-aag o 17-ag en combinacion con un inhibidor de proteasoma.
BRPI0610411A2 (pt) * 2005-04-29 2010-06-22 Kosan Biosciences Inc uso de 17-alilamino-17-demetoxigeldanamicina (17-aag) ou 17-aminogeldanamicina (17-ag) ou um pró-fármaco tanto de 17-aag ou 17-ag, bem como uma formulação farmacêutica
US20080032719A1 (en) * 2005-10-01 2008-02-07 Outland Research, Llc Centralized establishment-based tracking and messaging service
JP2008543941A (ja) * 2005-06-21 2008-12-04 インフィニティ・ディスカバリー・インコーポレイテッド アンサマイシン製剤およびその使用方法
WO2007035963A2 (en) * 2005-09-23 2007-03-29 Conforma Therapeutics Corporation Anti-tumor methods using multi drug resistance independent synthetic hsp90 inhibitors
CN101360492A (zh) * 2005-12-01 2009-02-04 康福玛医药公司 含安莎霉素的组合物
AU2007285057B2 (en) 2006-08-15 2013-08-01 Agency For Science, Technology And Research Mesenchymal stem cell conditioned medium
PE20081506A1 (es) 2006-12-12 2008-12-09 Infinity Discovery Inc Formulaciones de ansamicina
EP2121957A4 (de) * 2007-01-26 2010-11-10 Kosan Biosciences Inc Durch industrielle biosynthese gewonnene makrolactame
WO2008128063A1 (en) * 2007-04-12 2008-10-23 Infinity Discovery, Inc. Hydroquinone ansamycin formulations
NZ580313A (en) * 2007-04-12 2011-11-25 Joyant Pharmaceuticals Inc Smac mimetic dimers and trimers useful as anti-cancer agents
JP2011501731A (ja) * 2007-09-10 2011-01-13 ユニバーシティ オブ マサチューセッツ ミトコンドリア標的化抗腫瘍剤
WO2009086170A1 (en) * 2007-12-21 2009-07-09 Joyant Pharmaceuticals, Inc. Diazonamide analogs with improved solubility
JP5718648B2 (ja) 2008-02-22 2015-05-13 エイジェンシー・フォー・サイエンス，テクノロジー・アンド・リサーチ（エイ・スター） 間葉系幹細胞粒子
SG188918A1 (de) 2008-03-17 2013-04-30 Agency Science Tech & Res
EP2268146B1 (de) * 2008-04-29 2015-08-26 Joyant Pharmaceuticals, Inc. Indolin-antikrebsmittel
WO2009143485A1 (en) * 2008-05-22 2009-11-26 Joyant Pharmaceuticals, Inc. Diazonamide analogs
CN102245021B (zh) 2008-10-15 2014-09-17 无限药品公司 安莎霉素氢醌组合物
EP2471918A4 (de) 2009-09-29 2013-06-05 Takeda Pharmaceutical Screening-verfahren
JP5529282B2 (ja) 2009-10-28 2014-06-25 ジョイアント ファーマスーティカルズ、インク． 二量体Ｓｍａｃ模倣薬
EP2496711B1 (de) 2009-11-02 2016-02-17 Agency For Science, Technology And Research Verfahren zur überwachung von zellulären zuständen und zur immortalisierung von mesenchymalen stammzellen
SG183579A1 (en) 2011-02-11 2012-09-27 Agency Science Tech & Res Methods of detecting therapeutic exosomes
HUE037730T2 (hu) 2011-04-22 2018-09-28 Joyant Pharmaceuticals Inc Diazonamid analógok
EP2904119B1 (de) 2012-10-02 2020-06-17 The General Hospital Corporation d/b/a Massachusetts General Hospital Verfahren für mit dem dna-erfassungspfad assoziierten leiden
KR20160099081A (ko) 2013-07-26 2016-08-19 업데이트 파마 인코포레이트 비산트렌의 치료 효과 개선용 조합 방법
WO2015140005A1 (en) 2014-03-19 2015-09-24 Ifom Fondazione Istituto Firc Di Oncologia Molecolare Method of generation of pluripotent cells
EP3525806B1 (de) 2016-10-12 2023-02-15 Agency For Science, Technology And Research Verfahren zur lyophilisierung eines exosoms

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3987035A (en) * 1974-04-05 1976-10-19 University Of Illinois Foundation Biologically active compounds
US4261989A (en) * 1979-02-19 1981-04-14 Kaken Chemical Co. Ltd. Geldanamycin derivatives and antitumor drug

Also Published As

Publication number Publication date
JPH08503960A (ja) 1996-04-30
ATE166877T1 (de) 1998-06-15
EP0693073A1 (de) 1996-01-24
FI941580A (fi) 1994-10-08
US5387584A (en) 1995-02-07
FI106028B (fi) 2000-11-15
FI941580A0 (fi) 1994-04-06
CA2160137C (en) 1999-02-09
WO1994022867A1 (en) 1994-10-13
DK0693073T3 (da) 1998-10-12
DE69410790T2 (de) 1998-10-01
CA2160137A1 (en) 1994-10-13
JP2722280B2 (ja) 1998-03-04
ES2116594T3 (es) 1998-07-16
EP0693073B1 (de) 1998-06-03

Similar Documents

Publication Publication Date Title
DE69410790D1 (de) Bicyclische ansamycine und ihre verwendung als antitumormittel
ATE243694T1 (de) 4-mercaptoacetylamino-(2)benzazepinon(3)- derivate, und verwendung als enkephalinase- inhibitoren
DE69721008T2 (de) Bicyclische pyrimidine derivate und ihre verwendung als antikoagulantien
PT873340E (pt) Compostos heterociclicos de ciclopentano substituido
ATE248175T1 (de) Epothilonderivate und ihre verwendung als antitumormittel
BR0016878A (pt) Inibidores tricìclicos de cinases protéicas
PT934325E (pt) Trisanidridos biciclicos de tetrafosfonato
DE69620161T2 (de) Thrombininhibitoren
ATE225772T1 (de) Thrombin-inhibitoren
IL135302A0 (en) Bicyclic kinase inhibitors
DE69430611T2 (de) Phosphonooxymethyl oder Methylthiomethylether von Taxanderivaten als Antitumormittel
ES2106965T3 (es) Nuevas 4-aza-5alfa-androstan-3-onas 7beta-sustituidas como inhibidores de 5alfa-reductasa.
ATE242234T1 (de) Bicyclische arylcarboxamide und ihre therapeutische verwendung
BG103548A (en) Vitronectine receptor antagonists
MY111201A (en) New imidazopyridines
ATE129497T1 (de) Bicyclische pyranderivate und ihre verwendung als 5-lipoxygenasehemmer.
ES2186704T3 (es) Uso de antagonistas de crf.
ATE178886T1 (de) 1-aryl-2-acylamino-ethan-verbindungen und ihre verwendung als neurokinin- insbesondere als neurokinin-1-antagonisten
ATE184604T1 (de) Neue 2-substituierte tricyclische derivate von indan-2-mercaptoacetylamid verwendbar als enkephalinase inhibitoren
ATE176668T1 (de) Neue 9-n-bicyclische nucleosidverbindungen nützlich als selektive inhibitoren von proinflammatorische cytokinen
FI955118A (fi) Herbisidiset substituoidut 1-fenyyli- tai 1-pyridinyyli-bentsotriatsolit
TR200000005T2 (tr) Sıtmaya karşı ß-alkoksiakrilatlar.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee